Tango Therapeutics, Inc. (TNGX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $168.00K; Additional Paid in CapitalUSD $1.73B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-633.00K; Retained Earnings (Accumulated Deficit)USD $-704.01M.
- 2026-03-31: Common Stock, Value, IssuedUSD $144.00K; Additional Paid in CapitalUSD $1.04B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-115.00K; Retained Earnings (Accumulated Deficit)USD $-648.67M.
- 2025-12-31: Common Stock, Value, IssuedUSD $136.00K; Additional Paid in CapitalUSD $948.97M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $224.00K; Retained Earnings (Accumulated Deficit)USD $-603.15M.
- 2025-09-30: Common Stock, Value, IssuedUSD $112.00K; Additional Paid in CapitalUSD $724.20M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $121.00K; Retained Earnings (Accumulated Deficit)USD $-564.40M.
Tango Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Additional Paid in Capital, Common Stock USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $168.00K | $1.73B | $-633.00K | $-704.01M | $1.02B | 3 month · $16.89M | (m) | (m) | (m) |
| 2026-03-31 | $144.00K | $1.04B | $-115.00K | $-648.67M | $391.51M | 3 month · $10.80M | (m) | (m) | (m) |
| 2025-12-31 | $136.00K | $948.97M | $224.00K | $-603.15M | $346.18M | 12 month · $26.43M | (m) | (m) | (m) |
| 2025-09-30 | $112.00K | $724.20M | $121.00K | $-564.40M | $160.03M | 3 month · $6.62M | (m) | (m) | (m) |
| 2025-06-30 | $111.00K | $715.04M | $94.00K | $-580.29M | $134.95M | 3 month · $6.57M | (m) | (m) | (m) |
| 2025-03-31 | $108.00K | $707.89M | $194.00K | $-541.43M | $166.76M | 3 month · $7.25M | (m) | (m) | (m) |
| 2024-12-31 | $108.00K | $700.63M | $336.00K | $-501.56M | $199.52M | 12 month · $28.90M | (m) | (m) | (m) |
| 2024-09-30 | $107.00K | $692.20M | $750.00K | $-463.89M | $229.17M | 3 month · $7.18M | (m) | (m) | (m) |
| 2024-06-30 | $107.00K | $682.62M | $-334.00K | $-434.72M | $247.67M | 3 month · $7.54M | (m) | (m) | (m) |
| 2024-03-31 | $107.00K | $673.77M | $-257.00K | $-409.17M | $264.45M | 3 month · $6.72M | (m) | (m) | (m) |
| 2023-12-31 | $102.00K | $624.08M | $186.00K | $-371.26M | $253.11M | 12 month · $19.08M | (m) | (m) | (m) |
| 2023-09-30 | $102.00K | $617.67M | $-681.00K | $-340.49M | $276.60M | 3 month · $4.86M | (m) | (m) | (m) |
| 2023-06-30 | $88.00K | $532.60M | $-1.52M | $-318.23M | $212.94M | 3 month · $5.12M | (m) | (m) | (m) |
| 2023-03-31 | $88.00K | $526.90M | $-2.20M | $-297.52M | $227.26M | 3 month · $4.22M | (m) | (m) | (m) |
| 2022-12-31 | $88.00K | $522.61M | $-3.71M | $-269.51M | $249.48M | 12 month · $14.23M | (m) | (m) | (m) |
| 2022-09-30 | $88.00K | $518.29M | $-4.86M | $-240.45M | $273.07M | 3 month · $3.81M | (m) | (m) | (m) |
| 2022-06-30 | $88.00K | $514.37M | $-4.35M | $-211.40M | $298.70M | 3 month · $3.42M | (m) | (m) | (m) |
| 2022-03-31 | $88.00K | $510.22M | $-3.41M | $-186.54M | $320.36M | 3 month · $3.21M | (m) | (m) | (m) |
| 2021-12-31 | $88.00K | $506.76M | $-765.00K | $-161.34M | $344.75M | 12 month · $7.83M | (m) | 12 month · $6.00K | (m) |
| 2021-09-30 | $88.00K | $504.62M | $-10.00K | $-139.29M | $365.41M | 3 month · $3.43M | (m) | (m) | (m) |
| 2021-06-30 | $574.00 | (m) | (m) | $-1.13M | $54.89M | 3 month · $1.20M | $6.13M | 3 month · $3.00K | (m) |
| 2021-03-31 | $566.00 | (m) | (m) | $-362.80K | $57.89M | 3 month · $950.00K | $5.36M | 3 month · $2.00K | (m) |
| 2020-12-31 | $40.00K | $141.64M | $17.00K | $-103.10M | $38.60M | 12 month · $1.76M | $5.12M | 12 month · $12.00K | 7 month · $-9.62M |
| 2020-09-30 | $563.00 | (m) | (m) | $-52.86K | $46.91M | 3 month · $418.00K | $5.05M | 3 month · $3.00K | 3 month · $-9.62M |
| 2020-06-30 | (m) | (m) | (m) | (m) | $22.19M | 3 month · $407.00K | (m) | 3 month · $3.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $417.00K | 3 month · $408.00K | (m) | 3 month · $3.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $7.91M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |